A low dose of recombinant interleukin-1 protects granulocytopenic mice from lethal Gram-negative infection by Meer, J.W.M. van der et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
This full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/14801
 
 
 
Please be advised that this information was generated on 2014-11-11 and may be subject to
change.
Proc. Natl. Acad. Sci. USA
Vol. 85, pp. 1620-1623, March 1988
Im m unology
A low dose of recombinant interleukin 1 protects granulocytopenic 
mice from lethal Gram-negative infection
(immunomodulation/natural resistance/macrophages)
Jos W .  M .  v a n  d e r  M e e r * ^ ,  M i c h a e l  B a r z a * ,  S h e l d o n  M .  W o l f f * ,  a n d  C h a r l e s  A. D i n a r e l l o *
^Division of Geographic Medicinc and Infectious Diseases, Department of Medicine, Tufts University School of Medicine-New England Medical Center,  750 
Washington Street, Boston, MA 02111; and d e p a r t m e n t  of Infectious Diseases, University Hospital Leiden, Postbox 9600, 2300RC Leiden, The Netherlands
Communicated by Michael Sela, November 9, 1987 (received for review July 31, 1987)
ABSTRACT Natural and synthetic immunomodulators 
that increase nonspecific resistance to infection induce inter- 
leukin 1 (IL-1) production. Therefore, we investigated the 
effect of the administration of IL-1 on the survival of lethally 
infected granulocytopenic mice. Mice with cyclophosphamide- 
induced granulocytopenia were injected with approximately 
107 Pseudomonas aeruginosa in the thigh muscle at time 0; 
gentamicin was administered 6 hr and 23 hr later. When 
recombinant human IL-1/3 (one of the two forms of IL-1) was 
given as a single i.p. injection 24 hr before the infection, 
survival was increased. Using 80 ng of IL-1 p  per mouse, 
survival compared to control animals was 98% vs. 71% at 24 
hr, 98% vs. 60% at 30 hr, 86% vs. 36% at 36 hr, and 61% vs. 
11% at 48 hr {P <  0.001) after the infection. No effect of IL-1 
was observed when it was given 0.5 hr before or 6 hr after the 
infection. Animals not treated with gentamicin also benefited 
from the IL-1. Administration of the cyclooxygenase inhibitor 
ibuprofen did not affect the activity of IL-1. Numbers of 
bacteria cultured from the blood, thigh muscle, liver, spleen, 
and kidney were similar in IL-l-treated and control animals. 
Superoxide production by peritoneal macrophages was also 
similar in the two groups. These studies demonstrate that IL-1 
pretreatment protects granulocytopenic mice against lethal 
pseudomonas infection and suggest that this protection occurs 
through a noncellular mechanism.
For a number of decades, investigators have sought methods 
to enhance nonspecific resistance to infection (1-4). Several 
substances have been found that are able to increase natural 
resistance mechanisms. Most of these substances, such as 
lipopolysaccharides (2), BCG (bacillus Calmette-Guérin), 
and muramyl peptides (4) are derived from bacteria, and 
their administration has led to considerable toxicity. Despite 
efforts to modify toxicity [e.g., by the preparation of ana­
logues (4)J, these immunomodulatory substances have not 
gained acceptance as a therapy in humans.
The increase in natural resistance to infection produced by 
these substances may be due to enhancement of humoral (5) 
and/or cellular defense mechanisms. With respect to hu­
moral defense, hepatic acute-phase proteins and other non­
specific factors may play a role; with respect to cellular 
defenses, stimulation of mononuclear phagocytes is consid­
ered a major mechanism (6).
Substances that increase nonspecific resistance appear to 
be able to stimulate mononuclear phagocytes to synthesize 
and secrete interleukin 1 (IL-1) in vitro (7). IL-1 is the 
collective name for two 17-kDa proteins (IL-1/3 and IL-la) 
that have a number of important biological effects (7, 8). 
Because IL-1 is a major mediator of fever and other acute- 
phase responses, it is possible that many of the effects of the 
immunomodulatory substances mentioned above are medi-
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ated by this molecule. Therefore, we investigated the ability 
of recombinant IL-1 to ameliorate the outcome of a lethal 
bacterial infection in mice. We chose to study granulocyto­
penic mice in order to simulate the situation in neutropenic 
patients, in whom Gram-negative bacteremia is relatively 
common and the prognosis is grave. A portion of this work 
has previously been presented.§
MATERIALS AND METHODS
Mice. Female, 25-g Swiss-Webster mice (Taconic Farms, 
Germantown, NY) were kept in cages (six mice per cage) 
with filter lids and were fed standard lab chow and water ad 
libitum.
IL-1. Recombinant human IL-1/3 (kindly supplied by Cis- 
tron Biotechnology, Pine Brook, NJ) that contained less 
than 60 pg of endotoxin per mg of protein was used in the 
majority of the experiments. Recombinant IL-1 ¡3 from a 
different source (kindly provided by Alan Shaw, Biogen, 
Geneva) was also used in some experiments.
The IL-1 was given as a single i.p. injection in 2% (vol/ 
vol) normal mouse serum in 0.1 ml of pyrogen-free saline. 
Control mice received heat-inactivated (100°C for 20 min) 
IL-1. For the experiments with peritoneal macrophages (see 
below), IL-1 was given i.m.
Infection Models. Mice were rendered granulocytopenic 
(<0.5 x 109 granulocytes per liter) by means of i.p. injec­
tions of cyclophosphamide (Bristol Myers) at 150 and 100 
mg/kg of body weight 4 days and 1 day, respectively, before 
the inoculation of 1-2 x 107 Pseudomonas aeruginosa 
(ATCC no. 27853) in the thigh muscle as described else­
where (9, 10). Unless stated otherwise, doses of gentamicin 
(Lyomed, Rosemont, IL) at 120 mg/kg were given s.c. 6 and 
23 hr postinfection.
A similar infection was established using Streptococcus 
pneumoniae [107 colony-forming units (cfu) per mouse] 
obtained from the cerebrospinal fluid of a patient with 
pneumococcal meningitis. The time schedule for these ex­
periments was the same as with the P. aeruginosa. No 
antibiotic treatment was given except in a few experiments, 
in which benzylpenicillin (Pfizer) at 12 mg/kg was adminis­
tered s.c. 6 and 23 hr after infection.
The mice in each cage were randomized to receive either 
IL-1 at different time points and in different dosages or 
heat-inactivated IL-1. Survival was scored over a period of 
at least 48 hr. In one series of experiments with the pseu­
domonas model, mice were pretreated with a single s.c. 
injection of the cyclooxygenase inhibitor ibuprofen (Upjohn) 
at 10 mg/kg. For the experiments involving peritoneal
Abbreviations:  IL-1, interleukin 1; cfu, co lony-forming units.
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macrophages (see below), the two dosages of cyclophospha­
mide were administered s.c.
P e r i p h e r a l  Blood Leukocytes and Peritoneal Macrophages. 
Blood leukocytes obtained by cardiac puncture were 
c o u n t e d  in a hemocytometer, and smears were stained with 
Difquick (AHS Del Caribe, Aguada, Puerto Rico) for leu­
kocyte identification. Peritoneal cells were harvested as 
described elsewhere (11), washed twice in Ca2 + /M g2 + -free 
Hanks1 balanced salt solution, and counted. Preparations for 
light microscopy were made using a cytocentrifuge (Shannon 
Instruments) and Difquick stain.
The production of superoxide by peritoneal macrophages, 
as measured by the superoxide dismutase-inhibitable reduc­
tion of cytochrome c (Sigma) with 100 / j l M  phorbol 12- 
myristate 13-acetate (Sigma) as a stimulus, was assayed as 
described elsewhere (12).
In Vitro Antibacterial Effects of IL-1. We examined the 
possibility that IL-1 might have a direct antibacterial effect 
or might potentiate the antibacterial effect of gentamicin 
against P. aeruginosa. Using an automated spiral plater 
(Spiral Systems, Cincinnati, OH), we prepared a concentra­
tion gradient of IL-1 ranging from 0.15 to 42 ng/ml on the 
agar surface of Mueller-Hinton plates. After the plates had 
been dried, some were subjected to a second spiral plating of 
gentamicin with a concentration gradient ranging from 0.2 to 
30 /xg/ml. Radial streaks of P. aeruginosa from a suspension 
containing 108 cfu/ml were made on the plates. After incu­
bation overnight at 37°C, the distance from the center to the 
most central point of growth inhibition was measured. The 
effect of IL-1 alone was determined by comparing zones of 
inhibition in plates with and without IL-1. The effect of IL-1 
n the activity of gentamicin was determined by comparing 
the minimal inhibitory concentration of gentamicin in plates 
with and without IL-1.
Clearance of Bacteria. Twenty-four hours after pseudo- 
lonas infection, the granulocytopenic animals were killed 
by carbon dioxide asphyxia. Immediately after death, blood 
ultures were taken by cardiac puncture, and the muscles of 
the left thigh (the site of inoculation of the bacteria), the 
spleen, the kidney, and the liver were removed aseptically.
he tissue samples were weighed and were homogenized in 
sterile saline in a tissue grinder. To bring the number of cfu 
into the optimal range for reading, samples of thigh muscle 
ere diluted 1:10,000 and other samples were diluted 1:10 in 
lerile saline. The suspensions were then plated on sterile
C3
3
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Mueller-Hinton agar using the spiral plater. After overnight 
incubation at 37°C, the number of cfu was counted.
Statistical Analysis. Survival curves were analyzed using 
the Kaplan-Meier logarithm of rank test (13). Student’s t test 
was used to analyze the results of granulocyte numbers and 
macrophage function studies.
RESULTS
Survival of Mice. Human recombinant IL-1/3, given as a 
single i.p. injection of 80 ng, did not influence the survival of 
infected mice when it was given either shortly before or 6 hr 
after injection of P. aeruginosa. However, when IL-1 was 
given 24 hr before infection, dramatic improvement of sur­
vival was observed compared to the survival of controls {)C 
= 26.5, P < 0.001) (Fig. L4). The effect of IL-1 on survival 
was dose-dependent; dosages of 800, 80, or 8 ng per mouse 
afforded protection, whereas 0.8 ng was without effect (Fig. 
IB). In subsequent experiments we used the relatively low 
dose of 80 ng per mouse (3.0 ¿ig/kg). The results obtained 
with recombinant IL-1/3 from the two sources were similar.
When gentamicin treatment was withheld, the differences 
in survival between IL-l-treated mice and controls were still 
apparent (Fig. 1C). Pretreatment with a single injection of 
ibuprofen, given s.c. 30 min before the injection of IL-1, did 
not significantly influence the survival of either the IL-l- 
treated group or the control group.
In mice infected with S. pneumoniae, the differences 
between IL-l-treated and untreated mice were less promi­
nent. Although we observed increased survival with IL-1 in 
some experiments, the overall reproducibility of the IL-1 
effect was less clear with this microorganism than with P. 
aeruginosa (Fig. 2). Treatment with benzylpenicillin did not 
increase the differences between mice treated with IL-1 and 
controls.
Blood Leukocytes and Peritoneal Macrophages. At the time 
of infection and during the subsequent days, animals were 
profoundly granulocytopenic (Table 1). The recovery of gran­
ulocyte counts was approximately synchronous in mice 
treated with IL-1 and controls treated with heat-inactivated
IL-1.
The number of macrophages obtained from the unper­
turbed peritoneal cavities (cyclophosphamide given s.c. and 
IL-1 given i.m. for these experiments) was not different for 
IL-l-treated mice and controls (Table 1). Fewer than 0.5% of 
the peritoneal cells were granulocytes in these mice. Super-
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F i g .  1. Effect of IL-1/3 treatment on the survival of granulocytopenic mice. Recombinant human IL-1/3 was given as a single i.p. injection. 
Control mice received heat-inactivated (100°C for 20 min) IL-1. (A) Survival with IL-1 administered at different time points is depicted. There 
a ere 28-58 mice in each group. The survival with IL-1 given at -2 4  hr is significantly different from that in the control group (P < 0.001, x2 
26.5), whereas survival with IL-1 given at -3 0  min or +6 hr is not different from that in the control group. (B) Each group represents at 
least 21 mice. The survival rates are not significantly different between groups given 800 ng and 80 ng of IL-1, whereas survival rates in groups 
iven 800 ng, 80 ng, or 8 ng are significantly different (P < 0.05) from the survival rates in the control animals and those given 0.8 ng. (C) The 
number of mice is at least 18 per group. IL-1 was given at -2 4  hr at a dose of 80 ng. The difference in survival between IL-l-treated mice not 
treated with gentamicin and mice that received no treatment is significant at P < 0.05 (*2 = 6.26).
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F ig. 2. Survival o f  granulocytopenic  mice infected with S .  
p n e u m o n ia e .  Each group  represen ts  90 mice. IL-1 was given at -2 4  
hr at a dose  o f  80 ng. The  difference in survival between IL -l- t rea ted  
mice (□) and mice that received heat-inactivated IL-1 (♦) is not 
significant.
oxide production by macrophages from mice of the two 
groups was measured in three experiments using pooled 
peritoneal macrophages from six mice per group. The differ­
ences between cells of mice treated with IL-1 and controls 
were not statistically significantly different (two-tailed t test).
In Vitro Assessment of Antimicrobial Activity. No direct 
antibacterial effect of IL-1 could be demonstrated when the 
pseudomonas organisms were incubated with concentrations 
of IL-l/8 up to 42 ng/ml. Also, IL-1 did not potentiate the 
effect of gentamicin on the bacterium. The minimal inhibi­
tory concentration of gentamicin for P. aeruginosa was 1.8 
mg/liter.
Clearance of P. aeruginosa. In two sets of experiments, no 
differences in the numbers of bacteria in blood and tissues 
were found between mice treated with IL-1 or with heat- 
inactivated IL-1 (Fig. 3). When the data were expressed as 
number of microorganisms per organ rather than per gram of 
tissue, the data from two groups still did not differ.
DISCUSSION
In these studies, we report the efficacy of a relatively low 
dose of IL-1/3 (3.0 and 0.3 ¿¿g/kg) in preventing death in
Table  1. Effect o f  IL-l/3 on peripheral blood granulocytes  and 
peritoneal m acrophages  in cyclophospham ide-trea ted  mice
Mice
IL-1/3 treated Control
Blood granulocytes* ,  
no. x  10 ~ 9 per liter
Day 0 0.24 ±  0.04 0.20 ±  0.09
Day 1 0.13 ±  0.07 0.11 ±  0.07
Day 2 0.17 ±  0.10 0.24 ±  0.09
Day 3 0.54 ±  0.07 0.38 ±  0.04
Peritoneal m ac ro p h ag es1-,
no. x  10 9 per  liter 1.44 ±  0.19 1.45 ±  0.18
Superox ide  production*,
nmol per 106 cells 2.79 ±  0.21 3.38 ±  0.91
C yclophospham ide  was given i.p. for studies o f  blood granulo­
cy tes  and s.c. for s tudies o f  peritoneal m acrophages  at days - 4  and 
— 1. Mice were  injected with 80 ng o f  I L-l/3 or  heat-inactivated 
IL-1/3 (control) at day -  1 ; for studies o f  blood granulocytes ,  IL-1/3 
was given i .p . ,  and for studies o f  peritoneal m acrophages ,  it was 
given i.m. Values are the means ±  SE M .
*The n u m b er  o f  blood granulocytes  before administration o f  cyclo­
phospham ide  was (3.2 ±  0.7) x  109 per liter (mean ±  SEM). 
d e t e r m i n e d  at day 0 .
iS u pe rox ide  production  by m acrophages  from mice o f  the two 
groups  was m easured  at day 0 in three experim ents  using pooled 
peritoneal m acrophages  from six mice per group.
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Fig. 3. Bacterial c learance  in g ranu locy topen ic  mice following 
a P. a e ru g in o sa  infection. Mice received e i ther  80 ng o f  human 
re c o m b in a n t  IL-1/3 (s t ipp led  bars)  o r  h e a t - in a c t iv a te d  IL - 1/3 
(hatched bars) 24 hr before infection. Both groups  received a single 
s.c. injection of  gentamicin (120 m g/kg)  6 hr postinfection. Twenty- 
four hours after  infection, animals were  killed and cultures  were 
taken from thigh muscle,  b lood, liver, sp leen,  and  kidney. Each bar 
and e rro r  bar represen t  the mean ±  SE M  o f  c fu /g  o f  t issue in six 
mice.
severely leukopenic animals with a P. aeruginosa infection. 
These results hold promise that such treatment might de­
crease Gram-negative infections in patients with severe 
granulocytopenia. Patients whose granulocyte counts fall 
below 0.1 x 10y per liter are at high risk of acquiring 
Gram-negative bacterial infection (14, 15). In this circum­
stance, periodic prophylactic administration of IL-1, started 
when the number of granulocytes falls below 0.5 x 10y per 
liter, is a feasible option that should be explored further. It is 
likely that an equivalent dose of IL-1/3 employed in these 
studies can be used with acceptable toxicity in humans.
Because IL-1 is a major endogenous pyrogen (7, 8), an 
important side effect that can be anticipated is fever. There­
fore, our finding that pretreatment with the antipyretic drug 
ibuprofen did not influence the protective effect of IL-1 is 
relevant. Other studies have shown that indomethacin, an­
other cyclooxygenase inhibitor, in fact, increased nonspe­
cific resistance to infection (16).
The results of our studies demonstrating a protective 
effect expand upon those obtained by Kampschmidt and 
Pulliam (17), who used a partially purified rat cytokine 
preparation in Salmonella typhimurium infection, and those 
reported recently by Ozaki et al. (18). The latter investiga­
tors used human recombinant IL - la  in nonneutropenic mice 
that were infected with either P. aeruginosa or Klebsiella 
pneumoniae.
In the present studies, the time of administration of IL-1 in 
relation to time of infection was critical to the outcome. 
These findings are reminiscent of those in earlier studies 
(1-3, 5) in which bacterial endotoxin was given to mice 1 hr 
prior to infection (i.e., “ negative phase” ). The lack of any 
beneficial effect when IL-1 was given shortly before infec­
tion with P. aeruginosa may also be explained by the 
rapidity of the spread of the bacteria in granulocytopenic 
mice. The observation (18) that IL-1 was effective when 
given at the time of infection with Klebsiella in nongranu- 
locytopenic mice, in which host defenses may be adequate, 
is in agreement with this interpretation. A similar observa­
tion has been made previously with muramyl dipeptide in a 
model of intramuscular infection in normal mice (4).
The mechanisms responsible for the IL-l-induced increase 
in survival remain unclear. A direct antibacterial effect of 
IL-1 or a potentiation by IL-1 of the antibacterial effect of 
gentamicin was ruled out in vitro. The rapid clearance of i.p- 
injected recombinant IL-1/3 from the circulation (19) also 
makes a direct effect of the molecule on bacterial growth 
unlikely. Because the animals were profoundly granulocyto­
penic, an effect of IL-1 on the neutrophils was considered 
unlikely. Administration of IL-1 induces hypoferremia, 
which has an antimicrobial effect (20); however, this hypo-
i o7
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ferremic effect does not occur in granulocytopenic animals
(21), so it is unlikely to have played a role in our experi­
ments. Also, the beneficial effects of IL-1 on hematopoietic 
recovery (22) were not demonstrated in our short-term 
experiments.
An effect of IL-1 on macrophages could explain many of 
our results. The number of peritoneal macrophages and the 
ability of these cells to produce superoxide were not influ­
enced by treatment with IL-1. In this respect, the effects of 
IL-1 treatment do not completely mimic those of muramyl 
Jipeptide on macrophages (12). The most convincing argu­
ment against an effect on macrophage activation comes from 
the bacterial clearance data, which failed to demonstrate a 
difference between IL-l-treated and control mice. Appar­
ently, IL-l-treated mice survive better than control mice 
Jespite similar numbers of bacteria in their blood and in 
organs, including organs that contain the largest populations 
of mononuclear phagocytes.
The most likely explanation for the beneficial influence of 
I L - l  in our studies is through a humoral effect [for example, 
on acute-phase proteins such as an endotoxin-binding pro­
tein (23, 24)]. The time required for an optimal effect of IL-1 
in our model fits well with the time needed for the synthesis 
of most acute-phase proteins. The death of control mice, 
w hich began to occur approximately 1 hr after the second 
lose of gentamicin, could in fact be due to liberation of 
endotoxin by this antibiotic (25). Another possibility is that 
ihe protective effect of IL-1 may involve production of 
.ubstances that counteract the toxicity of pseudomonas 
cxotoxins. Our results with pneumococcal infection were 
^conclusive and do not shed further light on the precise 
mechanism of protection induced by IL-1.
Two other favorable effects of IL-1 treatment in experi- 
lental animals [namely, protection from lethal radiation (26) 
nd protection against oxygen damage (27)] are also pres- 
ntly unexplained, but, similar to our results, require 24-48 
hr of pretreatment with IL-1.
Recent reports indicate that high dosages (>1.8 mg/kg) of 
ecombinant interleukin 2 (IL-2) are also able to provide 
protection against death from infection in mice (28, 29). 
because high concentrations of IL-2 induce macrophages to 
produce and secrete IL-1 (30), the beneficial effects of IL-2 
can at least partially be explained by induction of IL-1.
In conclusion, prophylactic administration of a low dose 
>f IL-1/3 in order to increase natural resistance to infection is 
potentially feasible in high-risk patients (e.g., those with 
eclining granulocyte counts and at high risk for develop­
ment of a Gram-negative infection). The synergism of IL-1 
which is identical to hematopoietin 1 (22)] with factors such 
as granulocyte-macrophage colony-stimulating factor on he­
matopoietic recovery could further contribute to the poten­
tial utility of IL-1 as a therapeutic agent, especially in 
granulocytopenic patients.
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